New Insights into Chronic Pancreatitis: Potential Mechanisms Related to Probiotics
Abstract
:1. Introduction
2. Search Strategy
3. Alleviation of Small Intestinal Bacterial Overgrowth
4. Facilitation of Short-Chain Fatty Acids’ Production
5. Activation of Glucagon-like Peptide 1 Receptors in the Pancreas
Genus | Species | Disease Models | References |
---|---|---|---|
Lacticaseibacillus | L. paracasei L-21 | STC-1 cell line | [100] |
L. paracasei JY062 | Glycolipid metabolic disorders | [101] | |
L. casei CCFM419 | T2DM | [102] | |
L. rhamnosus NCDC 17 | [103] | ||
Lactiplantibacillus | L. plantarum subsp. plantarum MTCC5690 | T2DM | [104] |
Bifidobacterium | selenium-enriched B. longum DD98 | T2DM | [105] |
B. animalis subsp. lactis MN-Gup | [106] | ||
B. animalis subsp. lactis NJ241 | Parkinson’s disease | [107] | |
B. animalis subsp. lactis GCL2505 | Metabolic syndrome | [108] | |
B. longum subsp. longum B-53 | STC-1 cell line | [100] | |
Akkermansia | Pasteurized A. muciniphila | T2DM | [109] |
Bacteroides | B. thetaiotaomicron | alcoholic fatty liver disease | [110] |
Limosilactobacillus | L. fermentum MG4295 | T2DM | [111] |
L. fermentum MTCC5689 | [104] | ||
L. reuteri | Glucose metabolism disorder induced by acrylamide; glucose-tolerant humans | [112,113] | |
Clostridium | C. butyricum | Chronic unpredictable mild stress; T2DM | [114,115] |
6. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
Abbreviations
References
- Yadav, D.; Timmons, L.; Benson, J.T.; Dierkhising, R.A.; Chari, S.T. Incidence, prevalence, and survival of chronic pancreatitis: A population-based study. Am. J. Gastroenterol. 2011, 106, 2192–2199. [Google Scholar] [CrossRef] [PubMed]
- Yadav, D.; Muddana, V.; O’Connell, M. Hospitalizations for chronic pancreatitis in Allegheny County, Pennsylvania, USA. Pancreatology 2011, 11, 546–552. [Google Scholar] [CrossRef] [PubMed]
- Machicado, J.D.; Dudekula, A.; Tang, G.; Xu, H.; Wu, B.U.; Forsmark, C.E.; Yadav, D. Period prevalence of chronic pancreatitis diagnosis from 2001-2013 in the commercially insured population of the United States. Pancreatology 2019, 19, 813–818. [Google Scholar] [CrossRef]
- Petrov, M.S.; Olesen, S.S. Metabolic Sequelae: The Pancreatitis Zeitgeist of the 21st Century. Gastroenterology 2023, 165, 1122–1135. [Google Scholar] [CrossRef] [PubMed]
- Singh, V.K.; Yadav, D.; Garg, P.K. Diagnosis and Management of Chronic Pancreatitis: A Review. JAMA 2019, 322, 2422–2434. [Google Scholar] [CrossRef]
- Thomas, R.M.; Jobin, C. Microbiota in pancreatic health and disease: The next frontier in microbiome research. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 53–64. [Google Scholar] [CrossRef]
- Lupu, V.V.; Bratu, R.M.; Trandafir, L.M.; Bozomitu, L.; Paduraru, G.; Gimiga, N.; Ghiga, G.; Forna, L.; Ioniuc, I.; Petrariu, F.D.; et al. Exploring the Microbial Landscape: Gut Dysbiosis and Therapeutic Strategies in Pancreatitis—A Narrative Review. Biomedicines 2024, 12, 645. [Google Scholar] [CrossRef]
- Sanders, M.E.; Merenstein, D.J.; Reid, G.; Gibson, G.R.; Rastall, R.A. Author Correction: Probiotics and prebiotics in intestinal health and disease: From biology to the clinic. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 642. [Google Scholar] [CrossRef]
- Bures, J.; Cyrany, J.; Kohoutova, D.; Förstl, M.; Rejchrt, S.; Kvetina, J.; Vorisek, V.; Kopacova, M. Small intestinal bacterial overgrowth syndrome. World J. Gastroenterol. 2010, 16, 2978–2990. [Google Scholar] [CrossRef]
- Grace, E.; Shaw, C.; Whelan, K.; Andreyev, H.J.N. Review article: Small intestinal bacterial overgrowth-prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment. Pharmacol. Ther. 2013, 38, 674–688. [Google Scholar] [CrossRef]
- Pimentel, M.; Saad, R.J.; Long, M.D.; Rao, S.S.C. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am. J. Gastroenterol. 2020, 115, 165–178. [Google Scholar] [CrossRef]
- Zafar, H.; Jimenez, B.; Schneider, A. Small intestinal bacterial overgrowth: Current update. Curr. Opin. Gastroenterol. 2023, 39, 522–528. [Google Scholar] [CrossRef]
- El Kurdi, B.; Babar, S.; El Iskandarani, M.; Bataineh, A.; Lerch, M.M.; Young, M.; Singh, V.P. Factors That Affect Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Pancreatitis: A Systematic Review, Meta-Analysis, and Meta-Regression. Clin. Transl. Gastroenterol. 2019, 10, e00072. [Google Scholar] [CrossRef]
- Lee, A.A.; Baker, J.R.; Wamsteker, E.J.; Saad, R.; DiMagno, M.J. Small Intestinal Bacterial Overgrowth Is Common in Chronic Pancreatitis and Associates with Diabetes, Chronic Pancreatitis Severity, Low Zinc Levels, and Opiate Use. Am. J. Gastroenterol. 2019, 114, 1163–1171. [Google Scholar] [CrossRef]
- Ní Chonchubhair, H.M.; Bashir, Y.; Dobson, M.; Ryan, B.M.; Duggan, S.N.; Conlon, K.C. The prevalence of small intestinal bacterial overgrowth in non-surgical patients with chronic pancreatitis and pancreatic exocrine insufficiency (PEI). Pancreatology 2018, 18, 379–385. [Google Scholar] [CrossRef]
- Capurso, G.; Signoretti, M.; Archibugi, L.; Stigliano, S.; Delle Fave, G. Systematic review and meta-analysis: Small intestinal bacterial overgrowth in chronic pancreatitis. United Eur. Gastroenterol. J. 2016, 4, 697–705. [Google Scholar] [CrossRef]
- Rao, S.S.C.; Bhagatwala, J. Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management. Clin. Transl. Gastroenterol. 2019, 10, e00078. [Google Scholar] [CrossRef]
- Shah, S.C.; Day, L.W.; Somsouk, M.; Sewell, J.L. Meta-analysis: Antibiotic therapy for small intestinal bacterial overgrowth. Aliment. Pharmacol. Ther. 2013, 38, 925–934. [Google Scholar] [CrossRef]
- Redondo-Cuevas, L.; Belloch, L.; Martín-Carbonell, V.; Nicolás, A.; Alexandra, I.; Sanchis, L.; Ynfante, M.; Colmenares, M.; Mora, M.; Liebana, A.R.; et al. Do Herbal Supplements and Probiotics Complement Antibiotics and Diet in the Management of SIBO? A Randomized Clinical Trial. Nutrients 2024, 16, 1083. [Google Scholar] [CrossRef]
- Rosania, R.; Giorgio, F.; Principi, M.; Amoruso, A.; Monno, R.; Di Leo, A.; Ierardi, E. Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: A comparative evaluation. Curr. Clin. Pharmacol. 2013, 8, 169–172. [Google Scholar] [CrossRef]
- Khalighi, A.R.; Khalighi, M.R.; Behdani, R.; Jamali, J.; Khosravi, A.; Kouhestani, S.; Radmanesh, H.; Esmaeelzadeh, S.; Khalighi, N. Evaluating the efficacy of probiotic on treatment in patients with small intestinal bacterial overgrowth (SIBO)—A pilot study. Indian J. Med. Res. 2014, 140, 604–608. [Google Scholar] [PubMed]
- Soifer, L.O.; Peralta, D.; Dima, G.; Besasso, H. Comparative clinical efficacy of a probiotic vs. an antibiotic in the treatment of patients with intestinal bacterial overgrowth and chronic abdominal functional distension: A pilot study. Acta Gastroenterol. Latinoam. 2010, 40, 323–327. [Google Scholar] [PubMed]
- Zhong, C.; Qu, C.; Wang, B.; Liang, S.; Zeng, B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. J. Clin. Gastroenterol. 2017, 51, 300–311. [Google Scholar] [CrossRef]
- Aslan, I.; Tarhan Celebi, L.; Kayhan, H.; Kizilay, E.; Gulbahar, M.Y.; Kurt, H.; Cakici, B. Probiotic Formulations Containing Fixed and Essential Oils Ameliorates SIBO-Induced Gut Dysbiosis in Rats. Pharmaceuticals 2023, 16, 1041. [Google Scholar] [CrossRef]
- Barrett, J.S.; Canale, K.E.K.; Gearry, R.B.; Irving, P.M.; Gibson, P.R. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J. Gastroenterol. 2008, 14, 5020–5024. [Google Scholar] [CrossRef] [PubMed]
- Yao, C.K.; Barrett, J.S.; Philpott, H.; Chung, A.R.T.; van Langenberg, D.; Garg, M.; Gibson, P.R. Poor predictive value of breath hydrogen response for probiotic effects in IBS. J. Gastroenterol. Hepatol. 2015, 30, 1731–1739. [Google Scholar] [CrossRef]
- Lee, S.-H.; Joo, N.-S.; Kim, K.-M.; Kim, K.-N. The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study. Gastroenterol. Res. Pract. 2018, 2018, 8791916. [Google Scholar] [CrossRef]
- Luo, M.; Liu, Q.; Xiao, L.; Xiong, L.-S. Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation. J. Health Popul. Nutr. 2022, 41, 21. [Google Scholar] [CrossRef]
- Bustos Fernández, L.M.; Man, F.; Lasa, J.S. Impact of Saccharomyces boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study. Dig. Dis. 2023, 41, 798–809. [Google Scholar] [CrossRef]
- Hao, Y.; Xu, Y.; Ban, Y.; Li, J.; Wu, B.; Ouyang, Q.; Sun, Z.; Zhang, M.; Cai, Y.; Wang, M.; et al. Efficacy evaluation of probiotics combined with prebiotics in patients with clinical hypothyroidism complicated with small intestinal bacterial overgrowth during the second trimester of pregnancy. Front. Cell Infect. Microbiol. 2022, 12, 983027. [Google Scholar] [CrossRef]
- Zhang, M.; Xu, Y.; Sun, Z.; Ban, Y.; Zhai, S.; Wang, W.; Wang, M.; You, J.; Chen, D.; Zhu, S.; et al. Evaluation of probiotics in the treatment of hypothyroidism in early pregnancy combined with small intestinal bacterial overgrowth. Food Sci. Nutr. 2024, 12, 2671–2678. [Google Scholar] [CrossRef]
- Ouyang, Q.; Xu, Y.; Ban, Y.; Li, J.; Cai, Y.; Wu, B.; Hao, Y.; Sun, Z.; Zhang, M.; Wang, M.; et al. Probiotics and Prebiotics in Subclinical Hypothyroidism of Pregnancy with Small Intestinal Bacterial Overgrowth. Probiotics Antimicrob. Proteins 2024, 16, 579–588. [Google Scholar] [CrossRef] [PubMed]
- García-Collinot, G.; Madrigal-Santillán, E.O.; Martínez-Bencomo, M.A.; Carranza-Muleiro, R.A.; Jara, L.J.; Vera-Lastra, O.; Montes-Cortes, D.H.; Medina, G.; Cruz-Domínguez, M.P. Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. Dig. Dis. Sci. 2020, 65, 1134–1143. [Google Scholar] [CrossRef] [PubMed]
- Efremova, I.; Maslennikov, R.; Zharkova, M.; Poluektova, E.; Benuni, N.; Kotusov, A.; Demina, T.; Ivleva, A.; Adzhieva, F.; Krylova, T.; et al. Efficacy and Safety of a Probiotic Containing Saccharomyces boulardii CNCM I-745 in the Treatment of Small Intestinal Bacterial Overgrowth in Decompensated Cirrhosis: Randomized, Placebo-Controlled Study. J. Clin. Med. 2024, 13, 919. [Google Scholar] [CrossRef]
- Ferolla, S.M.; Couto, C.A.; Costa-Silva, L.; Armiliato, G.N.A.; Pereira, C.A.S.; Martins, F.S.; Ferrari, M.d.L.A.; Vilela, E.G.; Torres, H.O.G.; Cunha, A.S.; et al. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016, 8, 397. [Google Scholar] [CrossRef] [PubMed]
- Kwak, D.S.; Jun, D.W.; Seo, J.G.; Chung, W.S.; Park, S.-E.; Lee, K.N.; Khalid-Saeed, W.; Lee, H.L.; Lee, O.Y.; Yoon, B.C.; et al. Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease. Eur. J. Gastroenterol. Hepatol. 2014, 26, 1353–1359. [Google Scholar] [CrossRef]
- Liang, S.; Xu, L.; Zhang, D.; Wu, Z. Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer. Turk. J. Gastroenterol. 2016, 27, 227–232. [Google Scholar] [CrossRef]
- Kanika, G.; Khan, S.; Jena, G. Sodium Butyrate Ameliorates L-Arginine-Induced Pancreatitis and Associated Fibrosis in Wistar Rat: Role of Inflammation and Nitrosative Stress. J. Biochem. Mol. Toxicol. 2015, 29, 349–359. [Google Scholar] [CrossRef]
- Pan, L.-L.; Ren, Z.-N.; Yang, J.; Li, B.-B.; Huang, Y.-W.; Song, D.-X.; Li, X.; Xu, J.-J.; Bhatia, M.; Zou, D.-W.; et al. Gut microbiota controls the development of chronic pancreatitis: A critical role of short-chain fatty acids-producing Gram-positive bacteria. Acta Pharm. Sin. B 2023, 13, 4202–4216. [Google Scholar] [CrossRef]
- Sun, J.; Furio, L.; Mecheri, R.; van der Does, A.M.; Lundeberg, E.; Saveanu, L.; Chen, Y.; van Endert, P.; Agerberth, B.; Diana, J. Pancreatic β-Cells Limit Autoimmune Diabetes via an Immunoregulatory Antimicrobial Peptide Expressed under the Influence of the Gut Microbiota. Immunity 2015, 43, 304–317. [Google Scholar] [CrossRef]
- Vinolo, M.A.R.; Rodrigues, H.G.; Hatanaka, E.; Sato, F.T.; Sampaio, S.C.; Curi, R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J. Nutr. Biochem. 2011, 22, 849–855. [Google Scholar] [CrossRef]
- Park, J.-S.; Lee, E.-J.; Lee, J.-C.; Kim, W.-K.; Kim, H.-S. Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: Involvement of NF-kappaB and ERK signaling pathways. Int. Immunopharmacol. 2007, 7, 70–77. [Google Scholar] [CrossRef] [PubMed]
- Usami, M.; Kishimoto, K.; Ohata, A.; Miyoshi, M.; Aoyama, M.; Fueda, Y.; Kotani, J. Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr. Res. 2008, 28, 321–328. [Google Scholar] [CrossRef]
- Park, G.Y.; Joo, M.; Pedchenko, T.; Blackwell, T.S.; Christman, J.W. Regulation of macrophage cyclooxygenase-2 gene expression by modifications of histone H3. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 286, L956–L962. [Google Scholar] [CrossRef]
- Harada, E.; Kato, S. Effect of short-chain fatty acids on the secretory response of the ovine exocrine pancreas. Am. J. Physiol. 1983, 244, G284–G290. [Google Scholar] [CrossRef] [PubMed]
- Katoh, K.; Tsuda, T. Effects of secretagogues on membrane potential and input resistance of pancreatic acinar cells of sheep. Res. Vet. Sci. 1985, 38, 250–251. [Google Scholar] [CrossRef]
- Katoh, K.; Tsuda, T. Effects of acetylcholine and short-chain fatty acids on acinar cells of the exocrine pancreas in sheep. J. Physiol. 1984, 356, 479–489. [Google Scholar] [CrossRef]
- Katoh, K.; Tsuda, T. Effects of intravenous injection of butyrate on the exocrine pancreatic secretion in guinea pigs. Comp. Biochem. Physiol. A Comp. Physiol. 1987, 87, 569–572. [Google Scholar] [CrossRef]
- Lu, V.B.; Gribble, F.M.; Reimann, F. Free Fatty Acid Receptors in Enteroendocrine Cells. Endocrinology 2018, 159, 2826–2835. [Google Scholar] [CrossRef]
- Teyani, R.; Moniri, N.H. Gut feelings in the islets: The role of the gut microbiome and the FFA2 and FFA3 receptors for short chain fatty acids on β-cell function and metabolic regulation. Br. J. Pharmacol. 2023, 180, 3113–3129. [Google Scholar] [CrossRef]
- Rosli, N.S.A.; Abd Gani, S.; Khayat, M.E.; Zaidan, U.H.; Ismail, A.; Abdul Rahim, M.B.H. Short-chain fatty acids: Possible regulators of insulin secretion. Mol. Cell Biochem. 2023, 478, 517–530. [Google Scholar] [CrossRef]
- Frost, F.; Weiss, F.U.; Sendler, M.; Kacprowski, T.; Rühlemann, M.; Bang, C.; Franke, A.; Völker, U.; Völzke, H.; Lamprecht, G.; et al. The Gut Microbiome in Patients with Chronic Pancreatitis Is Characterized by Significant Dysbiosis and Overgrowth by Opportunistic Pathogens. Clin. Transl. Gastroenterol. 2020, 11, e00232. [Google Scholar] [CrossRef]
- Jandhyala, S.M.; Madhulika, A.; Deepika, G.; Rao, G.V.; Reddy, D.N.; Subramanyam, C.; Sasikala, M.; Talukdar, R. Altered intestinal microbiota in patients with chronic pancreatitis: Implications in diabetes and metabolic abnormalities. Sci. Rep. 2017, 7, 43640. [Google Scholar] [CrossRef]
- Moens, F.; Van den Abbeele, P.; Basit, A.W.; Dodoo, C.; Chatterjee, R.; Smith, B.; Gaisford, S. A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro. Int. J. Pharm. 2019, 555, 1–10. [Google Scholar] [CrossRef]
- Yang, S.; Shang, J.; Liu, L.; Tang, Z.; Meng, X. Strains producing different short-chain fatty acids alleviate DSS-induced ulcerative colitis by regulating intestinal microecology. Food Funct. 2022, 13, 12156–12169. [Google Scholar] [CrossRef]
- Zhang, Y.; Li, Y.; Wang, X.; Huang, J.; Feng, X.; Shi, C.; Yang, W.; Jiang, Y.; Cao, X.; Wang, J.; et al. Lactobacillus Plantarum NC8 and its metabolite acetate alleviate type 1 diabetes via inhibiting NLRP3. Microb. Pathog. 2023, 182, 106237. [Google Scholar] [CrossRef]
- Miao, X.; Jiang, Y.; Kong, D.; Wu, Z.; Liu, H.; Ye, X.; Gong, W. Lactobacillus rhamnosus HN001 Ameliorates BEZ235-Induced Intestinal Dysbiosis and Prolongs Cardiac Transplant Survival. Microbiol. Spectr. 2022, 10, e0079422. [Google Scholar] [CrossRef]
- Xu, B.; Wang, Z.; Wang, Y.; Zhang, K.; Li, J.; Zhou, L.; Li, B. Milk-derived Lactobacillus with high production of short-chain fatty acids relieves antibiotic-induced diarrhea in mice. Food Funct. 2024, 15, 5329–5342. [Google Scholar] [CrossRef]
- Byrne, C.S.; Chambers, E.S.; Morrison, D.J.; Frost, G. The role of short chain fatty acids in appetite regulation and energy homeostasis. Int. J. Obes. 2015, 39, 1331–1338. [Google Scholar] [CrossRef]
- Morrison, D.J.; Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 2016, 7, 189–200. [Google Scholar] [CrossRef]
- Pascale, N.; Gu, F.; Larsen, N.; Jespersen, L.; Respondek, F. The Potential of Pectins to Modulate the Human Gut Microbiota Evaluated by In Vitro Fermentation: A Systematic Review. Nutrients 2022, 14, 3629. [Google Scholar] [CrossRef]
- Macfarlane, S.; Macfarlane, G.T. Regulation of short-chain fatty acid production. Proc. Nutr. Soc. 2003, 62, 67–72. [Google Scholar] [CrossRef]
- Boets, E.; Deroover, L.; Houben, E.; Vermeulen, K.; Gomand, S.V.; Delcour, J.A.; Verbeke, K. Quantification of In Vivo Colonic Short Chain Fatty Acid Production from Inulin. Nutrients 2015, 7, 8916–8929. [Google Scholar] [CrossRef]
- François, I.E.J.A.; Lescroart, O.; Veraverbeke, W.S.; Marzorati, M.; Possemiers, S.; Evenepoel, P.; Hamer, H.; Houben, E.; Windey, K.; Welling, G.W.; et al. Effects of a wheat bran extract containing arabinoxylan oligosaccharides on gastrointestinal health parameters in healthy adult human volunteers: A double-blind, randomised, placebo-controlled, cross-over trial. Br. J. Nutr. 2012, 108, 2229–2242. [Google Scholar] [CrossRef]
- Guimarães, J.B.; Rodrigues, V.F.; Pereira, Í.S.; Manso, G.M.d.C.; Elias-Oliveira, J.; Leite, J.A.; Waldetario, M.C.G.M.; de Oliveira, S.; Gomes, A.B.D.S.P.; Faria, A.M.C.; et al. Inulin prebiotic ameliorates type 1 diabetes dictating regulatory T cell homing via CCR4 to pancreatic islets and butyrogenic gut microbiota in murine model. J. Leukoc. Biol. 2024, 115, 483–496. [Google Scholar] [CrossRef]
- Falony, G.; Vlachou, A.; Verbrugghe, K.; De Vuyst, L. Cross-feeding between Bifidobacterium longum BB536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose. Appl. Environ. Microbiol. 2006, 72, 7835–7841. [Google Scholar] [CrossRef]
- Moens, F.; Weckx, S.; De Vuyst, L. Bifidobacterial inulin-type fructan degradation capacity determines cross-feeding interactions between bifidobacteria and Faecalibacterium prausnitzii. Int. J. Food Microbiol. 2016, 231, 76–85. [Google Scholar] [CrossRef]
- Drucker, D.J. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018, 27, 740–756. [Google Scholar] [CrossRef]
- Müller, T.D.; Finan, B.; Bloom, S.R.; D’Alessio, D.; Drucker, D.J.; Flatt, P.R.; Fritsche, A.; Gribble, F.; Grill, H.J.; Habener, J.F.; et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 2019, 30, 72–130. [Google Scholar] [CrossRef]
- Nogueiras, R.; Nauck, M.A.; Tschöp, M.H. Gut hormone co-agonists for the treatment of obesity: From bench to bedside. Nat. Metab. 2023, 5, 933–944. [Google Scholar] [CrossRef]
- Drucker, D.J.; Habener, J.F.; Holst, J.J. Discovery, characterization, and clinical development of the glucagon-like peptides. J. Clin. Investig. 2017, 127, 4217–4227. [Google Scholar] [CrossRef]
- Richards, P.; Parker, H.E.; Adriaenssens, A.E.; Hodgson, J.M.; Cork, S.C.; Trapp, S.; Gribble, F.M.; Reimann, F. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 2014, 63, 1224–1233. [Google Scholar] [CrossRef]
- Waser, B.; Blank, A.; Karamitopoulou, E.; Perren, A.; Reubi, J.C. Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod. Pathol. 2015, 28, 391–402. [Google Scholar] [CrossRef]
- de Heer, J.; Rasmussen, C.; Coy, D.H.; Holst, J.J. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008, 51, 2263–2270. [Google Scholar] [CrossRef]
- Campbell, J.E.; Drucker, D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013, 17, 819–837. [Google Scholar] [CrossRef]
- Yusta, B.; Baggio, L.L.; Estall, J.L.; Koehler, J.A.; Holland, D.P.; Li, H.; Pipeleers, D.; Ling, Z.; Drucker, D.J. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 2006, 4, 391–406. [Google Scholar] [CrossRef]
- Lamont, B.J.; Andrikopoulos, S. Hope and fear for new classes of type 2 diabetes drugs: Is there preclinical evidence that incretin-based therapies alter pancreatic morphology? J. Endocrinol. 2014, 221, T43–T61. [Google Scholar] [CrossRef] [PubMed]
- Rankin, M.M.; Kushner, J.A. Adaptive beta-cell proliferation is severely restricted with advanced age. Diabetes 2009, 58, 1365–1372. [Google Scholar] [CrossRef]
- Tschen, S.-I.; Georgia, S.; Dhawan, S.; Bhushan, A. Skp2 is required for incretin hormone-mediated β-cell proliferation. Mol. Endocrinol. 2011, 25, 2134–2143. [Google Scholar] [CrossRef] [PubMed]
- Fiorentino, T.V.; Owston, M.; Abrahamian, G.; La Rosa, S.; Marando, A.; Perego, C.; Di Cairano, E.S.; Finzi, G.; Capella, C.; Sessa, F.; et al. Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates. Am. J. Pathol. 2015, 185, 139–150. [Google Scholar] [CrossRef]
- Hou, Y.; Ernst, S.A.; Heidenreich, K.; Williams, J.A. Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP. Am. J. Physiol. Gastrointest. Liver Physiol. 2016, 310, G26–G33. [Google Scholar] [CrossRef]
- Pyke, C.; Heller, R.S.; Kirk, R.K.; Ørskov, C.; Reedtz-Runge, S.; Kaastrup, P.; Hvelplund, A.; Bardram, L.; Calatayud, D.; Knudsen, L.B. GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014, 155, 1280–1290. [Google Scholar] [CrossRef]
- Kirk, R.K.; Pyke, C.; von Herrath, M.G.; Hasselby, J.P.; Pedersen, L.; Mortensen, P.G.; Knudsen, L.B.; Coppieters, K. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes. Diabetes Obes. Metab. 2017, 19, 705–712. [Google Scholar] [CrossRef]
- Koehler, J.A.; Baggio, L.L.; Lamont, B.J.; Ali, S.; Drucker, D.J. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009, 58, 2148–2161. [Google Scholar] [CrossRef]
- Koehler, J.A.; Baggio, L.L.; Cao, X.; Abdulla, T.; Campbell, J.E.; Secher, T.; Jelsing, J.; Larsen, B.; Drucker, D.J. Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. Diabetes 2015, 64, 1046–1056. [Google Scholar] [CrossRef]
- Steinberg, W.M.; Rosenstock, J.; Wadden, T.A.; Donsmark, M.; Jensen, C.B.; DeVries, J.H. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants with Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data from the SCALE Clinical Development Program. Diabetes Care 2017, 40, 839–848, Erratum in Diabetes Care 2018, 41, 1538. [Google Scholar] [CrossRef]
- Knapen, L.M.; de Jong, R.G.P.J.; Driessen, J.H.M.; Keulemans, Y.C.; van Erp, N.P.; De Bruin, M.L.; Leufkens, H.G.M.; Croes, S.; de Vries, F. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study. Diabetes Obes. Metab. 2017, 19, 401–411. [Google Scholar] [CrossRef]
- Yang, Y.; Yu, X.; Huang, L.; Yu, C. GLP-1R agonist may activate pancreatic stellate cells to induce rat pancreatic tissue lesion. Pancreatology 2013, 13, 498–501. [Google Scholar] [CrossRef]
- Zeng, Z.; Yu, R.; Zuo, F.; Zhang, B.; Peng, D.; Ma, H.; Chen, S. Heterologous Expression and Delivery of Biologically Active Exendin-4 by Lactobacillus paracasei L14. PLoS ONE 2016, 11, e0165130. [Google Scholar] [CrossRef]
- Hedin, K.A.; Zhang, H.; Kruse, V.; Rees, V.E.; Bäckhed, F.; Greiner, T.U.; Vazquez-Uribe, R.; Sommer, M.O.A. Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice. ACS Synth. Biol. 2023, 12, 3433–3442. [Google Scholar] [CrossRef]
- Wang, Q.; Guo, H.; Mao, W.; Qian, X.; Liu, Y. The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM. Pharmaceutics 2023, 15, 1202. [Google Scholar] [CrossRef]
- Wang, X.-L.; Chen, W.-J.; Jin, R.; Xu, X.; Wei, J.; Huang, H.; Tang, Y.-H.; Zou, C.-W.; Chen, T.-T. Engineered probiotics Clostridium butyricum-pMTL007-GLP-1 improves blood pressure via producing GLP-1 and modulating gut microbiota in spontaneous hypertension rat models. Microb. Biotechnol. 2023, 16, 799–812. [Google Scholar] [CrossRef]
- Wang, Y.; Shi, Y.; Peng, X.; Li, T.; Liang, C.; Wang, W.; Zhou, M.; Yang, J.; Cheng, J.; Zhang, Z.; et al. Biochemotaxis-Oriented Engineering Bacteria Expressing GLP-1 Enhance Diabetes Therapy by Regulating the Balance of Immune. Adv. Healthc. Mater. 2024, 13, e2303958. [Google Scholar] [CrossRef]
- Zhou, J.; Martin, R.J.; Tulley, R.T.; Raggio, A.M.; McCutcheon, K.L.; Shen, L.; Danna, S.C.; Tripathy, S.; Hegsted, M.; Keenan, M.J. Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am. J. Physiol. Endocrinol. Metab. 2008, 295, E1160–E1166. [Google Scholar] [CrossRef]
- Shen, L.; Keenan, M.J.; Raggio, A.; Williams, C.; Martin, R.J. Dietary-resistant starch improves maternal glycemic control in Goto-Kakizaki rat. Mol. Nutr. Food Res. 2011, 55, 1499–1508. [Google Scholar] [CrossRef]
- Hira, T.; Suto, R.; Kishimoto, Y.; Kanahori, S.; Hara, H. Resistant maltodextrin or fructooligosaccharides promotes GLP-1 production in male rats fed a high-fat and high-sucrose diet, and partially reduces energy intake and adiposity. Eur. J. Nutr. 2018, 57, 965–979. [Google Scholar] [CrossRef]
- Wongkrasant, P.; Pongkorpsakol, P.; Chitwattananont, S.; Satianrapapong, W.; Tuangkijkul, N.; Muanprasat, C. Fructo-oligosaccharides alleviate inflammation-associated apoptosis of GLP-1 secreting L cells via inhibition of iNOS and cleaved caspase-3 expression. J. Pharmacol. Sci. 2020, 143, 65–73. [Google Scholar] [CrossRef]
- Pichette, J.; Fynn-Sackey, N.; Gagnon, J. Hydrogen Sulfide and Sulfate Prebiotic Stimulates the Secretion of GLP-1 and Improves Glycemia in Male Mice. Endocrinology 2017, 158, 3416–3425. [Google Scholar] [CrossRef]
- Liu, H.; Xing, Y.; Wang, Y.; Ren, X.; Zhang, D.; Dai, J.; Xiu, Z.; Yu, S.; Dong, Y. Dendrobium officinale Polysaccharide Prevents Diabetes via the Regulation of Gut Microbiota in Prediabetic Mice. Foods 2023, 12, 2310. [Google Scholar] [CrossRef]
- Cheng, Z.; Chen, J.; Zhang, Y.; Li, X.; Zhang, N.; Liu, F.; Jiao, Y. In Vitro Hypoglycemic Activities of Lactobacilli and Bifidobacterium Strains from Healthy Children’s Sources and Their Effect on Stimulating GLP-1 Secretion in STC-1 Cells. Foods 2024, 13, 519. [Google Scholar] [CrossRef]
- Su, Y.; Ren, J.; Zhang, J.; Zheng, J.; Zhang, Q.; Tian, Y.; Zhang, Y.; Jiang, Y.; Zhang, W. Lactobacillus paracasei JY062 Alleviates Glucolipid Metabolism Disorders via the Adipoinsular Axis and Gut Microbiota. Nutrients 2024, 16, 267. [Google Scholar] [CrossRef] [PubMed]
- Wang, G.; Li, X.; Zhao, J.; Zhang, H.; Chen, W. Lactobacillus casei CCFM419 attenuates type 2 diabetes via a gut microbiota dependent mechanism. Food Funct. 2017, 8, 3155–3164. [Google Scholar] [CrossRef]
- Singh, S.; Sharma, R.K.; Malhotra, S.; Pothuraju, R.; Shandilya, U.K. Lactobacillus rhamnosus NCDC17 ameliorates type-2 diabetes by improving gut function, oxidative stress and inflammation in high-fat-diet fed and streptozotocintreated rats. Benef. Microbes 2017, 8, 243–255. [Google Scholar] [CrossRef]
- Balakumar, M.; Prabhu, D.; Sathishkumar, C.; Prabu, P.; Rokana, N.; Kumar, R.; Raghavan, S.; Soundarajan, A.; Grover, S.; Batish, V.K.; et al. Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high-fat diet-fed C57BL/6J mice. Eur. J. Nutr. 2018, 57, 279–295. [Google Scholar] [CrossRef]
- Zhao, D.; Zhu, H.; Gao, F.; Qian, Z.; Mao, W.; Yin, Y.; Tan, J.; Chen, D. Antidiabetic effects of selenium-enriched Bifidobacterium longum DD98 in type 2 diabetes model of mice. Food Funct. 2020, 11, 6528–6541. [Google Scholar] [CrossRef]
- Zhang, C.; Fang, B.; Zhang, N.; Zhang, Q.; Niu, T.; Zhao, L.; Sun, E.; Wang, J.; Xiao, R.; He, J.; et al. The Effect of Bifidobacterium animalis subsp. lactis MN-Gup on Glucose Metabolism, Gut Microbiota, and Their Metabolites in Type 2 Diabetic Mice. Nutrients 2024, 16, 1691. [Google Scholar] [CrossRef]
- Dong, Y.; Qi, Y.; Chen, J.; Han, S.; Su, W.; Ma, X.; Yu, Y.; Wang, Y. Neuroprotective Effects of Bifidobacterium animalis subsp. lactis NJ241 in a Mouse Model of Parkinson’s Disease: Implications for Gut Microbiota and PGC-1α. Mol. Neurobiol. 2024, 1–15. [Google Scholar] [CrossRef]
- Aoki, R.; Kamikado, K.; Suda, W.; Takii, H.; Mikami, Y.; Suganuma, N.; Hattori, M.; Koga, Y. A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. Sci. Rep. 2017, 7, 43522. [Google Scholar] [CrossRef] [PubMed]
- Niu, H.; Zhou, M.; Ji, A.; Zogona, D.; Wu, T.; Xu, X. Molecular Mechanism of Pasteurized Akkermansia muciniphila in Alleviating Type 2 Diabetes Symptoms. J. Agric. Food Chem. 2024, 72, 13083–13098. [Google Scholar] [CrossRef] [PubMed]
- Sangineto, M.; Grander, C.; Grabherr, F.; Mayr, L.; Enrich, B.; Schwärzler, J.; Dallio, M.; Bukke, V.N.; Moola, A.; Moschetta, A.; et al. Recovery of Bacteroides thetaiotaomicron ameliorates hepatic steatosis in experimental alcohol-related liver disease. Gut Microbes 2022, 14, 2089006. [Google Scholar] [CrossRef]
- Kim, J.E.; Lee, J.Y.; Kang, C.-H. Limosilactobacillus fermentum MG4295 Improves Hyperglycemia in High-Fat Diet-Induced Mice. Foods 2022, 11, 231. [Google Scholar] [CrossRef]
- Yue, Z.; Zhao, F.; Guo, Y.; Zhang, Y.; Chen, Y.; He, L.; Li, L. Lactobacillus reuteri JCM 1112 ameliorates chronic acrylamide-induced glucose metabolism disorder via the bile acid-TGR5-GLP-1 axis and modulates intestinal oxidative stress in mice. Food Funct. 2024, 15, 6450–6458. [Google Scholar] [CrossRef]
- Simon, M.-C.; Strassburger, K.; Nowotny, B.; Kolb, H.; Nowotny, P.; Burkart, V.; Zivehe, F.; Hwang, J.-H.; Stehle, P.; Pacini, G.; et al. Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: A proof of concept. Diabetes Care 2015, 38, 1827–1834. [Google Scholar] [CrossRef]
- Sun, J.; Wang, F.; Hu, X.; Yang, C.; Xu, H.; Yao, Y.; Liu, J. Clostridium butyricum Attenuates Chronic Unpredictable Mild Stress-Induced Depressive-Like Behavior in Mice via the Gut-Brain Axis. J. Agric. Food Chem. 2018, 66, 8415–8421. [Google Scholar] [CrossRef]
- Jia, L.; Li, D.; Feng, N.; Shamoon, M.; Sun, Z.; Ding, L.; Zhang, H.; Chen, W.; Sun, J.; Chen, Y.Q. Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice. Sci. Rep. 2017, 7, 7046. [Google Scholar] [CrossRef]
Probiotics | Products | References |
---|---|---|
Bifidobacterium bifidum H3-R2 | Acetate | [55] |
Lactiplantibacillus plantarum NC8 | Acetate | [56] |
Lacticaseibacillus rhamnosus HN001 | Propionate | [57] |
Propionibacterium freudenreichii B1 | Propionate | [55] |
Clostridium butyricum C1–6 | Butyrate | [55] |
Lactobacillus acidophilus KLDS 1.0901 | Acetate, propionate, butyrate | [58] |
Lactiplantibacillus plantarum KLDS 1.0386 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pan, Y.; Li, J.; Fan, Z.; Chen, Y.; Huang, X.; Wu, D. New Insights into Chronic Pancreatitis: Potential Mechanisms Related to Probiotics. Microorganisms 2024, 12, 1760. https://doi.org/10.3390/microorganisms12091760
Pan Y, Li J, Fan Z, Chen Y, Huang X, Wu D. New Insights into Chronic Pancreatitis: Potential Mechanisms Related to Probiotics. Microorganisms. 2024; 12(9):1760. https://doi.org/10.3390/microorganisms12091760
Chicago/Turabian StylePan, Yingyu, Jianing Li, Zhengyang Fan, Yonghao Chen, Xiaoxuan Huang, and Dong Wu. 2024. "New Insights into Chronic Pancreatitis: Potential Mechanisms Related to Probiotics" Microorganisms 12, no. 9: 1760. https://doi.org/10.3390/microorganisms12091760